Watch MDGL. Know when insiders buy.
One email the day a filing lands. Free.
Work order
39
FLAG · insiders 35, shorts 43
Insiders, 90 days
−$342K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $12.5BP/E —DIV YIELD —FCF YIELD -1.65%REV TTM $1.3B +149.0%NET INCOME −$325.1MNET DEBT $48.1M52W 412.35 – 602.83SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $364.3M | +71.2% | — | −$56.3M | −$57.9M | — | -1.99 | $23.3M | $4.3M | $19.1M | Jul 30 |
| Q1 2026 · Mar 31 | $311.3M | +126.8% | — | −$92.7M | −$94.4M | — | -3.25 | −$167.4M | $3.8M | −$171.3M | Jul 30 |
| Q4 2025 · Dec 31derived | $321.1M | +210.8% | — | −$59.6M | −$58.6M | — | -2.03 | −$133.5M | −$390K | −$133.1M | Jul 30 |
| Q3 2025 · Sep 30 | $287.3M | +362.0% | — | −$114M | −$114.2M | — | -4.01 | $79.8M | $857K | $79M | Jul 30 |
| Q2 2025 · Jun 30 | $212.8M | +1353.8% | — | −$47.2M | −$42.3M | — | -1.50 | −$47.1M | $0 | −$47.1M | Jul 30 |
| Q1 2025 · Mar 31 | $137.3M | — | 96.7% | −$79.3M | −$73.2M | — | -2.61 | −$88.9M | $0 | −$88.9M | Jul 30 |
| Q4 2024 · Dec 31derived | $103.3M | — | — | −$67M | −$59.4M | — | 2.00 | −$104.5M | $195K | −$104.7M | Jul 30 |
| Q3 2024 · Sep 30 | $62.2M | — | — | −$116.3M | −$107M | — | -4.92 | −$67M | $779K | −$67.8M | Nov 4 |
| Q2 2024 · Jun 30 | $14.6M | — | — | −$162.5M | −$152M | — | -7.10 | −$134.9M | $131K | −$135.1M | Nov 4 |
| Q1 2024 · Mar 31 | $0 | — | — | −$152M | −$147.5M | — | -7.38 | −$149.2M | $357K | −$149.5M | Nov 4 |
| Q4 2023 · Dec 31 | $0 | — | — | −$117.2M | −$112.2M | — | -5.68 | −$79.9M | $1M | −$81M | Jul 30 |
| Q3 2023 · Sep 30 | $0 | — | — | −$98.5M | −$98.7M | — | -5.34 | −$84.9M | $339K | −$85.3M | Oct 31 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $958.4M | — | −$300.1M | −$288.3M | -30.1% | -10.15 | −$189.6M | $467K | −$190M | — | — |
| FY2024 · to Dec 31 | $180.1M | 96.5% | −$497.9M | −$465.9M | -258.6% | -17.31 | −$455.6M | $1.5M | −$457M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$380.5M | −$373.6M | — | -17.33 | −$324.2M | $1.5M | −$325.7M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$293.6M | −$295.4M | — | -17.23 | −$224.9M | $217K | −$225.1M | — | — |
| FY2021 · to Dec 31 | $0 | — | −$242.5M | −$241.8M | — | -14.63 | −$183.9M | $209K | −$184.1M | — | — |
| FY2020 · to Dec 31 | $0 | — | −$206.7M | −$202.2M | — | -13.09 | −$157.6M | $334K | −$157.9M | — | — |
Every number comes from MADRIGAL PHARMACEUTICALS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.